Difference between revisions of "Apocrine carcinoma of the breast"
Jump to navigation
Jump to search
(→IHC) |
(→IHC) |
||
Line 66: | Line 66: | ||
*ER -ve. | *ER -ve. | ||
*PR -ve. | *PR -ve. | ||
*often Her2 -ve | *often Her2 +ve but can be Her2 -ve | ||
Notes | Notes | ||
*Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile. | *Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile. | ||
*Apocrine carcioma can be a non-basal type 'triple negative carcinoma' | *Apocrine carcioma can be a non-basal type 'triple negative carcinoma' <ref>{{Cite journal | last1 = Tsutsumi | first1 = Y. | title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. | journal = Jpn J Clin Oncol | volume = 42 | issue = 5 | pages = 375-86 | month = May | year = 2012 | doi = 10.1093/jjco/hys034 | PMID = 22450930 }}</ref>. | ||
**May show different behaviour to other types of triple negative carcinoma | **May show different behaviour to other types of triple negative carcinoma | ||
**May respond to treatments targeting the androgen receptor<ref>{{Cite journal | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume = | issue = | pages = | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }} | **May respond to treatments targeting the androgen receptor<ref>{{Cite journal | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume = | issue = | pages = | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }} | ||
</ref> | </ref> | ||
*Be careful when reading the literature in this area - is the author discussing 'molecular apocrine' (ER -ve, AR +ve) or 'morphologic apocrine' carcinoma. | |||
*Many ductal carcinomas, NOS will show AR positivity but are often ER +ve. | |||
==See also== | ==See also== |
Revision as of 11:58, 1 April 2015
Apocrine carcinoma of the breast | |
---|---|
Diagnosis in short | |
| |
LM | apocrine morphology (cells with prominent nucleoli - may be multiple, abundant granular eosinophilic cytoplasm) - must be >=90% of tumour, loss of basal cells |
LM DDx | glycogen-rich clear cell carcinoma of the breast |
IHC | AR +ve, GCDFP-15 +ve, ER -ve, PR -ve |
Site | breast - see invasive breast cancer |
| |
Prevalence | uncommon |
Apocrine carcinoma of the breast is a rare form of invasive breast cancer.
General
- Need >=90% apocrine morphology.[1]
Microscopic
Features:[1]
- Prominent nucleoli.
- Often multiple.[2]
- Abundant granular eosinophilic cytoplasm.
- Architecture like invasive ductal carcinomas no special type.
DDx:
- Glycogen-rich clear cell carcinoma of the breast.
- Cutaneous Apocrine Carcinoma
- A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum.
Images
www:
IHC
Smaller tumours classically:[3]
- AR +ve.
- GCDFP-15 +ve.
Usually:[1]
- ER -ve.
- PR -ve.
- often Her2 +ve but can be Her2 -ve
Notes
- Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile.
- Apocrine carcioma can be a non-basal type 'triple negative carcinoma' [4].
- May show different behaviour to other types of triple negative carcinoma
- May respond to treatments targeting the androgen receptor[5]
- Be careful when reading the literature in this area - is the author discussing 'molecular apocrine' (ER -ve, AR +ve) or 'morphologic apocrine' carcinoma.
- Many ductal carcinomas, NOS will show AR positivity but are often ER +ve.
See also
References
- ↑ 1.0 1.1 1.2 O'Malley, Frances P.; Pinder, Sarah E. (2006). Breast Pathology: A Volume in Foundations in Diagnostic Pathology series (1st ed.). Churchill Livingstone. pp. 217. ISBN 978-0443066801.
- ↑ O'Malley, FP.; Bane, A. (Jan 2008). "An update on apocrine lesions of the breast.". Histopathology 52 (1): 3-10. doi:10.1111/j.1365-2559.2007.02888.x. PMID 18171412.
- ↑ Honma, N.; Takubo, K.; Akiyama, F.; Sawabe, M.; Arai, T.; Younes, M.; Kasumi, F.; Sakamoto, G. (Aug 2005). "Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.". Histopathology 47 (2): 195-201. doi:10.1111/j.1365-2559.2005.02181.x. PMID 16045781.
- ↑ Tsutsumi, Y. (May 2012). "Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.". Jpn J Clin Oncol 42 (5): 375-86. doi:10.1093/jjco/hys034. PMID 22450930.
- ↑ Safarpour, D.; Tavassoli, FA. (Oct 2014). "A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers.". Arch Pathol Lab Med. doi:10.5858/arpa.2014-0122-RA. PMID 25310144.